Human protein tyrosine phosphatase inhibitors and methods of...

Details Human protein tyrosine phosphatase inhibitors and methods of... Human protein tyrosine phosphatase inhibitors and methods of...

2007-06-26

2009-11-24

Stockton, Laura L. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S365000

Reexamination Certificate

active

07622593

ABSTRACT:
The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.

REFERENCES:
patent: 4673641 (1987-06-01), George et al.
patent: 5424398 (1995-06-01), Middeldorp et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5807819 (1998-09-01), Cheng et al.
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 6033908 (2000-03-01), Bout et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6589758 (2003-07-01), Zhu
patent: 6596722 (2003-07-01), Moltzen et al.
patent: 7226755 (2007-06-01), Peters et al.
patent: 7507568 (2009-03-01), Evdokimov
patent: 2004/0167183 (2004-08-01), Klopfenstein et al.
patent: 2004/0204863 (2004-10-01), Kim et al.
patent: 2007/0299116 (2007-12-01), Gray
patent: 2008/0004267 (2008-01-01), Gray
patent: 2008/0076764 (2008-03-01), Peters et al.
patent: WO 00/65085 (2000-11-01), None
patent: WO 00/65088 (2000-11-01), None
patent: WO 02/26774 (2002-04-01), None
Annex et al., “Growth Factor-Induced Therapeutic Angiogenesis in the Heart: Protein Therapy,”Cardiovascular Research, 65(3):649-655 (2005).
Ardelt et al., “Estradiol Regulates Angiopoietin-1 mRNA Expression Through Estrogen Receptor-α in a Rodent Experimental Stroke Model,”Stroke, 36:337-341 (2005).
Auerbach et al., “Angiogenesis Assays: A Critical Overview,”Clinical Chemistry, 49:32-40 (2003).
Carano et al., “Angiogenesis and Bone Repair,”Drug Discovery Today, 8(21):980-989 (2003).
Carvalho et al., “The Role of Angiogenesis in a Murine Tibial Model of Distraction Osteogenesis,”Bone, 34:849-861 (2004).
Kugathasan et al.,“Role of Angiopoietin-1 in Experimental and Human Pulmonary Arterial Hpertension,”Chest, 128:633-642 (2005).
Shiojima et al., “Disruption of Coordinated Cardiac Hypertrophy and Angiogenesis Contributes to the Transition to Heart Failure,”Journal of Clinical Invest., 115(8):2108-2118 (2005).
Siddiqui et al, “Combination of angiopoietin-1 and vascular endothelial growth factor gene therapy enhances arteriogenesis in the ischemic myocardium,”Biochem. Biophys. Res. Comm., 310:1002-1009 (2003).
Simons, “Angiogenesis: Where Do We Stand Now?,”Circulation, 111:1556-1566 (2005).
Simons et al., “Clinical Trials in Coronary Angiogenesis,”Circulation, 102:73-86 (2000).
Takahashi et al., “Adenoviral-Delivered Angiopoietin-1 Reduces the Infarction and Attenuates the Progression of Cardiace Dysfunction in the Rate Model of Acute Myocardial Infarction,”Molecular Therapy. 8(4):584-592 (2003).
Thurston, “Complimentary Actions of VEGF and Angiopoietin-1 on Blood Vessel Growth and Leakage,”J. Anat., 200:575-580 (2002).
Vailhe et al., “In Vitro Models of Vasculogenesis and Angiogenesis,”Laboratory Investigation, 81:439-452 (2001).
Zhang et al., “Vascular Endothelial Growth Factor and Angiopoietins in Focal Cerebral Ischemia,”Trends Cardiovascular Med., 12(2):62-66 (2002).
PCT/US2007/014823, filed Feb. 8, 2008, Response to International Search Report and Amendment Under PCT Article 19.
PCT/US2007/014824, filed Feb. 8, 2008, Response to International Search Report and Amendment Under PCT Article 19.
U.S. Appl. No. 10/634,027, filed Jan. 19, 2006, Restriction and/or Election Requirement.
U.S. Appl. No. 10/634,027, filed Feb. 13, 2006, Response to Restriction Requirement.
U.S. Appl. No. 10/634,027, filed Apr. 13, 2006, Non-Final Office Action.
U.S. Appl. No. 10/634,027, filed Oct. 16, 2006, Reply After 1stOffice Action.
U.S. Appl. No. 10/634,027, filed Nov. 22, 2006, Final Office Action.
U.S. Appl. No. 10/634,027, filed May 21, 2007, Amendment After Final Office Action.
U.S. Appl. No. 10/634,027, filed Jun. 12, 2007, Non-Final Office Action.
U.S. Appl. No. 10/634,027, filed Sep. 17, 2007, Amendment in Response to Non-Final Office Action.
U.S. Appl. No. 10/634,027, filed Nov. 9, 2007, Final Office Action.
U.S. Appl. No. 10/634,027, filed May 8, 2008, Amendment and Response to Final Office Action.
U.S. Appl. No. 10/634,027, filed Jun. 17, 2008, Non-Final Office Action.
U.S. Appl. No. 11/821,846, filed Jun. 26, 2007, Jeffrey Lyle Gray.
U.S. Appl. No. 11/821,868, filed Jun. 26, 2007, Jeffrey Lyle Gray.
Bussolino, F., “Molecular Mechanisms of Blood Vessel Formation,” Trends Biochem. Sci., 22, 251-256, 1997.
Folkman, et al., “Tumor Angiogenesis,” Chapter 10, 206-32, The Molecular Basis of Cancer, Mendelsohn et al., eds., W. B. Saunders, 1995.
Kruegar, et al., “Structural Diversity and Evolution of Human Receptor-Like Protein Tyrosine Phosphatases,” EMBO J., 9, 1990, p. 3241-3252.
Nguyen, L. L., et al., “Cellular Interactions in Vascular Growth and Differentiation,” Int. Rev. Cytol., 204, 1-48, 2001.
O'Reilly, et al., “Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma,” Cell, 79, 315-28, 1994.
O'Reilly, et al., Cell, “Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth,” 88, 277-85, 1997.
Teischer et al., “Potentiation of Cytotoxic Cancer Therapies By TNP-470 Alone and With Other Anti-Angiogenic Agents,” Int. J. Cancer, 57, 920-25, 1994.
Weidner, “Tumor Angiogenesis and Metastasis—Correlation In Invasive Breast Carcinoma,” New England J. Med., 324, 1, 108, 1991.
Altschul et al., “Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs,”Nucleic Acids Res., 25(27):3389-3402 (1997).
Barany et al., “Solid-phase Peptide Synthesis: A Silver Anniversary Report,”Int. J. Peptide Protein Res., 30(6):705-739 (1987).
Bartlett et al., “Molecular Recognition in Chemical and Biological Problems; Cavet: A Program to Facilitate the Structure-Derived Design of Biologically Active Molecules,”Special Pub., Royal Chem. Soc., 78:182-196 (1989).
Bohm, “The Computer Program LUDI: A New Method for the De Novo Design of Enzyme Inhibitors,”J. Comuter-Aided. Molec. Design, 6(1):61-78 (1992).
Chanteau et al., “Synthesis of Anthropomorphic Molecules: The NanoPutians,”J. Org. Chem., 68:8750-8766 (2003).
Cohen et al., “Molecular Modeling Software and Methods for Medicinal Chemistry,”J. Med. Chem., 33(3):883-894 (1990).
Fachinger et al., “Functional Interaction of Vascular Endothelial-Protein-Tyrosine Phosphatase with the Angiopoietin Receptor Tie-2,”Oncogene, 18:5948-5953 (1999).
Flower, “Modelling G-Protein-Coupled Receptors for Drug Design,”Biochimica et Biophysica Acta, 1422:207-234 (1999).
Gaits et al., “Increase in Receptor-like Protein Tyrosine Phosphatase Activity and Express Level on Density-Dependent Growth Arrest of Endothelial Cells,”Biochem J., 311:97-103 (1995).
Goodford, “A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules,”J. Med. Chem., 28(7):849-57 (1985).
Goodsell et al., “Automated Docking of Substrates to Proteins by Simulated Annealing,”Proteins Struct. Funct. Genet. 8:195-202 (1990).
Harder et al., “Characterization and Kinetic Analysis of the Intracellular Domain of Human Protein Tyrosine Phosphatase β (HPTPβ) Using Synthetic Phosphopeptides,”Biochem. J., 296:395-401 (1994).
Henikoff et al., “Amino Acid Substitution Matrices from Protein Blocks,”Proc. Natl. Acad. Sci. USA89:10915-10919 (1992).
Hopkins et al., “Inhibitors of Kinesin Activity from Structure-Based Computer Screening,”Biochemistry, 39:2805-2814 (2000).
Huang et al., “HCPTPA, a Protein Tyrosine Phosphatase that Regulates Vascular Endothelial Growth Factor Receptor-Mediated Signal Transduction an

Affiliated with

Also associated with

Rating

Human protein tyrosine phosphatase inhibitors and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human protein tyrosine phosphatase inhibitors and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human protein tyrosine phosphatase inhibitors and methods of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4092770